Several studies have shown that positive PD‐L1 is correlated with the occurrence of PE in NSCLC patients,12, 24, 25 suggesting that immunotherapy targeting PD‐1/PD‐L1 axis might have a protective effect against PE. This evidence concerns the gene CD274 and non-small cell lung carcinoma.